Organogenesis
This article was originally published in The Gray Sheet
Executive Summary
Forms subsidiary ECM Pharma to "develop medical devices and pharmaceutically active compounds based upon natural components of the extracellular matrix," the firm reports. ECM Pharma's initial plans are to "supply cell-produced human collagen...for evaluation, testing, and ultimate use in medical devices, drug delivery, research, and manufacturing." The subsidiary, based in Organogenesis' Canton, Massachusetts facility, "expects to license issued and pending" patent applications for "production of cultured human collagen" and "the assembly of collagen into various forms and shapes"